Autologous stem cell transplantation for multiple myeloma in the era of novel agents.
Autologous stem cell transplantation for multiple myeloma in the era of novel agents. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):14-5 Authors: Shimazaki C PMID: 24461805 [PubMed - in process]
This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1007/s00520-020-05770-w.
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Mahmut Yeral, Pelin Aytan, Burcu Gungor, Can Boga, Ali Unal, Yener Koc, Leylagul Kaynar, Nurhilal Buyukkurt, Bulent Eser, Hakan Ozdoğu
Publication date: Available online 19 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Panayotis Kaloyannidis, Rawan Omari, Eman Eldebawy, Eshrak Al Shaibani, John Apostolidis, Taghreed Hindi, Heba Raslan, Ayed Al Garni, Ahmed Al Buali, Khalid Al Anezi, Hani Al Hashmi
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Al-Ola Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Shebli Atrash, Hameem Kawsar, Monia Sigle, Leyla Shune, Joseph McGuirk, Siddhartha Ganguly
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yu-juan Xue, Yi-fei Cheng, Ai-dong Lu, Yu Wang, Ying-xi Zuo, Chen-hua Yan, Pan Suo, Le-ping Zhang, Xiao-jun Huang
Involved field radiotherapy has been used in the peri-transplant period to minimize the risk of disease recurrence after autologous stem cell transplantation in patients with bulky or residual lymphoma post-salvage chemotherapy. However, the optimal timing of radiotherapy still remains under investigation. We used involved field radiotherapy early post-transplant, in high risk patients, demonstrating high survival rates with extremely low toxicity.
The number of therapeutic options for patients with RRMM has increased significantly. We treated 18 patients with RRMM with DPd as salvage therapy followed by HDCT/ASCT. The ORR after salvage treatment with DPd was 100%. ORR on day 100 post-ASCT was 100%, 67% achieved ≥CR. There was no reported treatment-related mortality on day 100. The 2-year PFS and 2- year OS rate were 83.3% ad 94.4%, respectively
The treatment option for children with intermediate-risk acute myeloid leukemia (IR-AML) in first complete remission is controversial. We retrospectively analyzed the outcomes of 80 children with IR-AML, and compared the effect of chemotherapy with haplo-HSCT as post-remission treatment. Compared with chemotherapy group, haplo-HSCT group had a significantly lower risk of relapse, especially in patients with minimal residual disease ≥10-3 after induction therapy.
We analyzed data on 326 MM patients who had received novel agents based induction prior to autologous stem cell transplant at our center to evaluate impact of induction therapy on transplant outcomes. The triplet based induction was superior as regards to response (95.4% versus 84.02% (doublets), p